Bionomics (BNOX) Stock Price, News & Analysis

Company Overview

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.

Key Stats

• Today's Range: $0.27 to $0.30
• 50-Day Range: $0.19 to $0.68
• 52-Week Range: $0.18 to $1.95
• Volume: 446,549 shs
• Average Volume: 28.79 million shs
• Market Capitalization: $5.10 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.00
• Consensus Rating: Buy

Bionomics Stock Analysis - MarketRank™

Bionomics scored higher than 52% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Bionomics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Bionomics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Bionomics are expected to grow in the coming year, from ($1.03) to ($0.42) per share.

Price to Book Value per Share Ratio

Bionomics has a P/B Ratio of 0.30. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.10% of the outstanding shares of Bionomics have been sold short.

Short Interest Ratio / Days to Cover

Bionomics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bionomics has recently increased by 1,278.99%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bionomics does not currently pay a dividend.

Dividend Growth

Bionomics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.10% of the outstanding shares of Bionomics have been sold short.

Short Interest Ratio / Days to Cover

Bionomics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bionomics has recently increased by 1,278.99%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.30

News Sentiment

Bionomics has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Bionomics this week, compared to 0 articles on an average week.

Search Interest

7 people have searched for BNOX on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Bionomics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Bionomics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.69% of the stock of Bionomics is held by insiders.

Percentage Held by Institutions

Only 15.90% of the stock of Bionomics is held by institutions.

BNOX Stock Analysis - Frequently Asked Questions

How have BNOX shares performed this year?

Bionomics' stock was trading at $1.48 on January 1st, 2024. Since then, BNOX stock has decreased by 80.1% and is now trading at $0.2946.
View the best growth stocks for 2024 here.

When did Bionomics IPO?

Bionomics (BNOX) raised $20 million in an IPO on Thursday, December 16th 2021. The company issued 1,622,000 shares at $12.35 per share.

How do I buy shares of Bionomics?

Shares of BNOX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Bionomics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bionomics investors own include Meta Platforms (META), Palantir Technologies (PLTR), PayPal (PYPL), Intel (INTC), ChargePoint (CHPT), CRISPR Therapeutics (CRSP) and NVIDIA (NVDA).

Company Calendar

• Today: 11/24/2024
• Fiscal Year End: 6/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BNOX
• CUSIP: N/A
• CIK: 1191070
• Web: www.bionomics.com.au
• Phone: 088-150-7400
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $8.00
• High Stock Price Target: $8.00
• Low Stock Price Target: $8.00
• Potential Upside/Downside: +2,615.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.30
• Quick Ratio: 3.30

Sales & Book Value

• Annual Sales: $10,000.00
• Price / Sales: 510.18
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.99 per share
• Price / Book: 0.30

Miscellaneous

• Outstanding Shares: 17,320,000
• Free Float: 17,200,000
• Market Cap: $5.10 million
• Optionable: Not Optionable
• Beta: -0.07